Cenobamate for the treatment of focal epilepsies

References

• Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology. 2017;88:296–303.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Reese JP, Dodel R, et al. Cost of epilepsy: a systematic review. Pharmacoeconomics. 2008;26:463–476.
   PubMed Web of Science ®Google Scholar
• Riechmann J, Strzelczyk A, Reese JP, et al. Costs of epilepsy and cost-driving factors in children, adolescents, and their caregivers in Germany. Epilepsia. 2015;56:1388–1397.
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314–319.
   PubMed Web of Science ®Google Scholar
• Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med. 2011;365:919–926.
   PubMed Web of Science ®Google Scholar
• Löscher W, Potschka H, Sisodiya SM, et al. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72:606–638.
   PubMed Web of Science ®Google Scholar
• Smeets VM, van Lierop BA, Vanhoutvin JP, et al. Epilepsy and employment: literature review. Epilepsy Behav. 2007;10:354–362.
   PubMed Web of Science ®Google Scholar
• Thurman DJ, Logroscino G, Beghi E, et al.; Epidemiology Commission of the International League Against E. The burden of premature mortality of epilepsy in high-income countries: A systematic review from the mortality task force of the international league against epilepsy. Epilepsia. 2017;58:17–26.
   PubMed Web of Science ®Google Scholar
• Riechmann J, Willems LM, Boor R, et al. Quality of life and correlating factors in children, adolescents with epilepsy, and their caregivers: A cross-sectional multicenter study from Germany. Seizure. 2019;69:92–98.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Griebel C, Lux W, et al. The burden of severely drug-refractory epilepsy: a comparative longitudinal evaluation of mortality, morbidity, resource use, and cost using German health insurance data. Front Neurol. 2017;8:712.
   PubMed Web of Science ®Google Scholar
• Callaghan B, Schlesinger M, Rodemer W, et al. Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia. 2011;52:619–626.
   PubMed Web of Science ®Google Scholar
• Mula M, Zaccara G, Galimberti CA, et al. Validated outcome of treatment changes according to international league against epilepsy criteria in adults with drug-resistant focal epilepsy. Epilepsia. 2019;60:1114–1123.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Cho JH, Shin H, et al. Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019;855:175–182.
   PubMed Web of Science ®Google Scholar
• Younus I, Reddy DS. A resurging boom in new drugs for epilepsy and brain disorders. Expert Rev Clin Pharmacol. 2018;11:27–45.
   PubMed Web of Science ®Google Scholar
• Sharma R, Nakamura M, Neupane C, et al. Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate. Eur J Pharmacol. 2020;879:173117.
   PubMed Web of Science ®Google Scholar
• Dinsmore S Clinical Review NDA 212839 (cenobamate) XCOPRI. Center for Drug Evaluation and Research, U.S. Food and Drug Administration 2019; [cited 2020 Jun 28] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212839Orig1s000MedR.pdf
   Google Scholar
• Vernillet L, Greene SA, Kamin M. Pharmacokinetics of cenobamate: results from single and multiple oral ascending-dose studies in healthy subjects. Clin Pharmacol Drug Dev. 2020;9:428–443.
   PubMed Web of Science ®Google Scholar
• Vernillet L, Greene SA, Kim HW, et al. Mass balance, metabolism, and excretion of cenobamate, a new antiepileptic drug, after a single oral administration in healthy male subjects. Eur J Drug Metab Pharmacokinet. 2020. DOI:10.1007/s13318-020-00615-7
   PubMed Web of Science ®Google Scholar
• Prescribing information for XCOPRI. U.S. Food and drug administration 2019 [cited 2020 Jun 28] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf
   Google Scholar
• DGA K-NT, DiVentura BD, Pollard JR, et al. Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089). Neurology. 2019;93:e559–e567.•Proof-of-concept study on cenobamate in photosensitive epilepsy.
   PubMed Web of Science ®Google Scholar
• Chung SS, French JA, Kowalski J, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94:e2311–e2322.••Pivotal CO13 RCT showing efficacy of cenobamate 200 mg vs. placebo.
   PubMed Web of Science ®Google Scholar
• Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19:38–48.••Pivotal CO17 study showing efficacy of cenobamate 100–400 mg vs. placebo.
   PubMed Web of Science ®Google Scholar
• Costa J, Fareleira F, Ascencao R, et al. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia. 2011;52:1280–1291.
   PubMed Web of Science ®Google Scholar
• Willems LM, Watermann N, Richter S, et al. Incidence, risk factors and consequences of epilepsy-related injuries and accidents: a retrospective, single center study. Front Neurol. 2018;9:414.
   PubMed Web of Science ®Google Scholar
• Ryvlin P, Nashef L, Lhatoo SD, et al. Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study. Lancet Neurol. 2013;12:966–977.
   PubMed Web of Science ®Google Scholar
• Sperling MR, Klein P, Aboumatar S, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61:1099–1108.•Large open-label CO21 study on cenobamate in 1339 patients.
   Web of Science ®Google Scholar
• Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019. Allergol Int. 2019;68:301–308.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med. 2011;124:588–597.
   PubMed Web of Science ®Google Scholar
• Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48:1223–1244.
   PubMed Web of Science ®Google Scholar
• Arnold S. Cenobamate: new hope for treatment-resistant epilepsy. Lancet Neurol. 2020;19:23–24.
   PubMed Web of Science ®Google Scholar
• French JA. Cenobamate for focal seizures - a game changer? Nat Rev Neurol. 2020;16:133–134.
   PubMed Web of Science ®Google Scholar
• Mudigoudar B, Wheless J. Safety of adjunctive treatment with cenobamate in patients with uncontrolled focal seizures. Lancet Neurol. 2020;19:288.
   PubMed Web of Science ®Google Scholar
• Vossler DG. Remarkably high efficacy of cenobamate in adults with focal-onset seizures: a double-blind, randomized, placebo-controlled trial. Epilepsy Curr. 2020;20:85–87.
   PubMed Web of Science ®Google Scholar
• Wechsler RT, Yates SL, Messenheimer J, et al. Lacosamide for uncontrolled primary generalized tonic-clonic seizures: an open-label pilot study with 59-week extension. Epilepsy Res. 2017;130:13–20.
   PubMed Web of Science ®Google Scholar
• Reif PS, Manner A, Willems LM, et al. Intravenous lacosamide for treatment of absence status epilepticus in genetic generalized epilepsy: A case report and review of literature. Acta Neurol Scand. 2018;138:259–262.
   PubMed Web of Science ®Google Scholar
• Brodie MJ. Sodium channel blockers in the treatment of epilepsy. CNS Drugs. 2017;31:527–534.
   PubMed Web of Science ®Google Scholar
• Keam SJ. Cenobamate: first approval. Drugs. 2020;80:73–78.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Willems LM, Willig S, et al. Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol. 2015;8:733–740.
   PubMed Web of Science ®Google Scholar
• Rohracher A, Zimmermann G, Villanueva V, et al. Perampanel in routine clinical use across Europe: pooled, multicenter, observational data. Epilepsia. 2018;59:1727–1739.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Klein KM, Willems LM, et al. Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol. 2016;9:637–645.
   PubMed Web of Science ®Google Scholar
• Willems LM, Bauer S, Rosenow F, et al. Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus. Expert Opin Pharmacother. 2019;20:1755–1765.
   PubMed Web of Science ®Google Scholar
• Willems LM, Bauer S, Jahnke K, et al. Therapeutic options for patients with refractory status epilepticus in palliative settings or with a limitation of life-sustaining therapies: a systematic review. CNS Drugs. 2020;34:801–826.
   PubMed Web of Science ®Google Scholar